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1ABSTRACT
Anti-proliferative and Apoptotic Activities of Müllerian Inhibiting 
Substance Combined with Calcitriol in Ovarian Cancer Cell Lines
Yeon Soo Jung
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Young Tae Kim)
Purpose This study aimed to investigate whether Müllerian inhibiting 
substance (MIS) in combination with calcitriol modulates proliferation 
and apoptosis of human ovarian cancer (OCa) cell lines (SKOV3, 
OVCAR3, and OVCA433) and identify the signaling pathway by which 
MIS mediates apoptosis.
Materials and Methods OCa cell lines were treated with MIS in the 
absence or presence of calcitriol. Cell viability and proliferation were 
evaluated using the Cell Counting Kit-8 assay and apoptosis was 
evaluated by DNA fragmentation assay. Western blot and enzyme-linked 
immunosorbent assay were used to determine the signaling pathway.
Results The cells showed specific staining for the MIS type II receptor. 
Treatment of OCa cells with MIS and calcitriol led to dose- and time-
dependent inhibition of cell growth and survival. The combination 
treatment significantly suppressed cell growth, down-regulating the 
expression of B-cell lymphoma 2 (Bcl-2); and up-regulating the 
expression of Bcl-2 associated X protein (BAX), caspase-3, and 
caspase-9 through the extracellular signal-regulated kinase signaling 
pathway.
2Conclusion These results, coupled with a much-needed decrease in the 
toxic side effects of currently employed therapeutic agents, provide a 
strong rationale for testing the therapeutic potential of MIS, alone or in 
combination with calcitriol, in the treatment of OCa.
.
----------------------------------------------------------------------------------------
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I. INTRODUCTION
Epithelial ovarian cancer (OCa) affects nearly 25,000 women in North America 
every year and is the fifth most common malignancy in women with a five-year 
mortality of over 70%.1 Because the symptoms are often not observed until the 
cancer has spread extensively, less than 25% of women are diagnosed with early 
stage disease. Combined surgery and cytotoxic therapy produce favorable 
clinical responses in 50% to 80% of patients; however, the majority of patients 
relapse. Therefore, it is crucial to search for new biologically targeted treatment 
modalities.2, 3
The Müllerian duct, which is formed from the coelomic epithelium, develops 
into the Fallopian tubes, uterus, cervix, proximal vagina, and the surface 
epithelium of the ovaries in females.4 Müllerian inhibiting substance (MIS), also 
referred to as anti-Müllerian hormone or AMH, is a glycoprotein composed of 
two identical 535 amino acid subunits with a combined molecular weight of 140 
kDa. MIS belongs to the transforming growth factor- β (TGF-β) family along 
with bone morphogenetic protein, activin, and inhibin.5 Several studies have 
suggested that MIS inhibits the growth of cell lines and tissues of MIS 
receptor-expressing gynecological malignancies such as breast, endometrial, 
4cervical, and ovarian cancer. 6-10
Calcitriol (1, 25 – dihydroxycholecalciferol), the hormonally active form of 
Vitamin D (Vit D), has long been known as an important regulator of calcium 
homeostasis and bone metabolism through its activity in the intestines, bones, 
kidneys, and the parathyroid glands.11 Emerging evidence indicates that calcitriol 
may be implicated in the regulation of other important biological processes such 
as insulin secretion, immune response, pro-differentiation, anti-proliferation, 
pro-apoptosis, anti-angiogenesis, inhibition of invasion and metastasis, and 
antiiflammation.12
Recently, it has been suggested that MIS constitutes a novel target regulated by 
calcitriol in prostate cells and that induction of MIS expression may play an 
important role in the anti-cancer activity of calcitriol. 13, 14
Growing evidence suggesting that MIS and calcitriol can act synergistically to 
inhibit the growth of tumor cells prompted us to examine the effects of MIS in 
combination with calcitriol on OCa cell lines. Therefore, the purpose of this 
study was to investigate whether MIS in combination with calcitriol modulates 
the proliferation and apoptosis of human OCa cell lines (SKOV3, OVCAR3, and 
OVCA433) and to identify the signaling pathway by which MIS and calcitriol 
mediate proliferation and apoptosis.
II. MATERIALS AND METHODS
1. Cell culturing
Human epithelial OCa cell lines (SKOV3, OVCAR3, and OVCA433) were 
cultured in RPMI-1640 medium (Gibco-BRL, Gaithersburg, MD, USA) 
supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 
μg/mL streptomycin. The cells were incubated in a humidified atmosphere
containing 5% CO2 at 37°C. 
52. MIS type II receptor (MISRII) detection
MISRII expression was examined in SKOV3, OVCAR3, and OVCA433 cell 
lines by Western blot analysis performed with rabbit polyclonal antihuman 
MISRII antiserum (Abcam, Cambridge, MA, USA). 
3. Cell viability and proliferation assay
Cell viability and proliferation were measured using the Cell Counting Kit-8 
(CCK-8) assay (Dojindo Laboratories, Kumamoto, Japan). Cells were seeded in 
a 96-well flat-bottomed plate (2 × 103 cells in 100 μL per well), incubated 
overnight to allow for cell attachment and recovery, then exposed to MIS 
(USCN Life Science Inc., Wuhan, Hubei, China) and calcitriol (Sigma, St. Louis, 
Mo, USA) dissolved in methanol for 24, 48, 72, and 96 h. Next, CCK-8 solution 
(10 μL) was added to each well and the cells were incubated for an additional 
two hours. Absorbance at 450 nm was measured with a microplate reader. 
4. Treatment of cells with inhibitors
Cells were seeded at a density of 5 × 103 cells/100-mm dish. Following the 
48-h incubation, the cells were washed with a serum-free medium and then 
transferred into media without FBS at least 16 h prior to the start of the 
experiments. Cells were pretreated with 20 μM of each of the following 
inhibitors: SB203580 (Sigma), a p38 mitogen-activated protein kinase (p38 
MAPK) inhibitor; PD98059 (Sigma), an extracellular signal-regulated kinase 
(ERK) inhibitor; LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor; and 
SP600125 (Sigma), a c-Jun amino-terminal kinase (JNK) inhibitor. 
5. Western blot analysis
Following treatment, cells were collected and centrifuged and whole-cell 
lysates were prepared using a lysis buffer. The protein concentration was 
6measured using the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, 
CA, USA). Thirty micrograms of protein was directly separated by 10% 
SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to 
polyvinylidene difluoride (PVDF, Bio-Rad Laboratories). Blocked membranes 
were then incubated with primary antibodies at 4°C overnight. B-cell lymphoma 
2 (Bcl-2), Bcl-2 associated X protein (BAX), ERK, phospho-ERK, JNK, and 
phosphor-JNK purchased from Cell signaling Technology (Beverly, MA, USA); 
and caspase-3 and caspase-9 purchased from Biovision (Milpitas, CA, USA) 
were used at a 1:1000 dilution. Subsequent to washing, the membranes were 
incubated with a horseradish peroxidase-conjugated anti-rabbit or anti-mouse 
secondary antibody (SantaCruz, Biotechnology, SantaCruz, CA, USA). The 
blots were re-probed with anti-β-actin antibody as a loading control. Protein 
bands were visualized using an enhanced chemiluminescence system (ECLTM; 
Amersham, Little Chalfont, UK) and band intensities were quantified using the 
Luminescent image analyzer (LAS 4000 mini; Fujifilm, Uppsala, Sweden). All 
experiments were independently repeated three times. 
6. DNA fragmentation assay
The DNA fragmentation assay was performed using enzyme-linked 
immunosorbent assay (ELISA) with a DNA fragmentation Kit (Roche Applied 
Science, Indianapolis, IN, USA). Cells were seeded at a density of 1 × 105 cells 
per well in 96-well plates. Subsequent to 24 h growth, the medium was changed 
to a serum-free medium and cells were grown for an additional 24 h. In order to 
label the DNA, the medium was replaced with 10% FBS-Dulbecco’s modified 
Eagle medium, 10 μM 5-bromo-2’-deoxyuridine was added to each well, and
cells were incubated for 24 h. Cells were treated with calcitriol for 4 h and then 
incubated with MIS for an additional 96 h. Cells were then lysed in 200 μL
incubation buffer and soluble DNA fragments were quantified using the Cellular 
7DNA fragmentation ELISA kit according to the manufacturer’s instructions. All 
experiments were performed in triplicate. 
7. Statistical analysis
Data were analyzed by Student’s t-test or ANOVA for each of the repeated 
experiments. For all analyses, statistically significant differences were 
designated as P < 0.05. Results are shown as mean ± SD.
III. RESULTS
1. MISRII is expressed in ovarian cancer cell lines
Prior to evaluating the response of OCa cells to MIS, we first determined 
whether the cells expressed MISRII. Expression of MISRII was examined in 
SKOV3, OVCAR3, and OVCA433 cell lines by Western blot analysis 
performed with a rabbit polyclonal antihuman MISRII antiserum. All cell lines 
showed specific staining for MISRII although expression in OVCAR3 was 
higher than in SKOV3 and OVCA433 (data not shown).
2. Growth inhibitory concentrations for MIS and calcitriol
OCa cells were treated with a range of MIS and calcitriol concentrations 
(35.5–284 nM of MIS and 1-100 μM of calcitriol) to determine the IC50 for each 
cell line. For all subsequent experiments, MIS and calcitriol concentrations were 
held constant at or near their IC50, 71 nM and 50 μM, respectively (Fig. 1). 
8Fig. 1. Effects of MIS and calcitriol on the viability of ovarian cancer (OCa) 
cells. Cells were treated with a range of MIS and calcitriol concentrations 
(35.5–284 nM of MIS and 1–100 μM of calcitriol) to determine the IC50 for each 
cell line. Values are presented as a percentage of the control and were calculated 
using the following equation: ([mean absorbance of treated cells]/[mean 
absorbance of control cells]) × 100. Data are expressed as mean ± SD from three 
independent experiments. For all subsequent experiments, MIS and calcitriol 
concentrations were held constant at or near their IC50, 71 nM and 50 μM, 
respectively. MIS, Müllerian inhibiting substance.
9Fig. 2. Viability and proliferation assays conducted with ovarian cancer (OCa) 
cell lines treated with MIS and calcitriol (Relative cell growth as a function of 
time). MIS and calcitriol concentrations were held constant at or near their IC50; 
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71 nM MIS and 50 μM calcitriol. Cells were treated with vehicles (control), 71 
nM MIS (MIS), 50 μM calcitriol (calcitriol), or both agents (MIS + calcitriol). 
Combined use of calcitriol and MIS reduces cell proliferation of human OCa cell 
lines (SKOV3, OVCAR3, and OVCA433). Cell growth was monitored for 96 h 
post treatment. For the combination treatment, cells were pretreated with 
calcitriol (50 μM) for 4 h prior to the addition of MIS (71 nM). Cell proliferation 
was measured using the Cell Counting Kit-8 solution as described in the 
Materials and Methods section of this paper. Results are representative of three 
experiments. Data in the bar graph represent mean ± SD. *P < 0.05 vs. control; 
†P < 0.05 vs. MIS. MIS, Müllerian inhibiting substance.
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3. Cooperative effects of MIS and calcitriol on suppression of ovarian 
cancer cell proliferation
SKOV3, OVCAR3 and OVCA433 cells were grown in plates for 48 h then 
treated with 71 nM MIS and 50 μM calcitriol; 24, 48, 72, and 96 h post treatment, 
the cells were incubated with CCK-8 solution and the absorbance was read at 450 
nm. Cell proliferation decreased significantly following 72 h exposure to MIS 
combined with calcitriol (Fig. 2).
4. Calcitriol enhanced MIS-induced apoptosis in ovarian cancer cell lines
The degree of apoptosis was analyzed using ELISA measuring the level of 
cellular DNA fragmentation. A significant increase in DNA fragmentation was 
apparent in cells treated with MIS (71 nM) combined with calcitriol (50 μM) 
compared with the control-treated cells (MIS 0 nM) and calcitriol-treated cells. In 
addition, the results for the combination treatment were significantly different 
from MIS treatment alone in all cell lines (Fig. 3).
12
Fig. 3. Calcitriol enhances MIS-induced apoptosis in OCa cell lines. Cells (1 × 
105/well) were pretreated with or without calcitriol (50 μM) for 4 h prior to the 
addition of MIS (71 nM). Apoptosis was measured as cellular DNA fragmentation 
determined by ELISA. Results are representative of three experiments. Significant 
inhibition relative to the control (MIS 0 nM) is indicated by an asterisk and the 
cross indicates a significant difference relative to the MIS treatment (MIS 71 nM). 
13
Data are presented as mean ± SD. *P < 0.05 vs. control; †P < 0.05 vs. MIS. MIS, 
Müllerian inhibiting substance; ELISA, enzyme-linked immunosorbent assay; 
OD, optical density.
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5. MIS and calcitriol alter the expression of regulatory proteins in SKOV3
To demonstrate that MIS and calcitriol-reduced cell proliferation was due to 
apoptotic activity, the levels of Bcl-2, BAX, caspase-3, and caspase-9 were 
examined and compared with vehicle controls. SKOV3 cells were pretreated with 
or without calcitriol (50 μM) for 4 h prior to the addition of MIS (71 nM). 
Following 48 h incubation, cells were analyzed by Western blot analysis with 
anti-caspase-9 antibody and anti-caspase-3 antibody; the expression of the 
apoptosis-related proteins Bcl-2 and BAX was also evaluated. Treatment of 
SKOV3 with MIS combined with calcitriol induced apoptosis, as evidenced by an 
increase in the level of BAX, caspase-3 and caspase-9, and a decrease in the levels 
of Bcl-2 (Fig. 4A, B).
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Fig. 4. MIS and calcitriol alter the expression of regulatory proteins in SKOV3. 
Cells were treated with vehicles (control), 71 nM MIS (MIS), 50 μM calcitriol 
(calcitriol), or both agents (MIS + calcitriol). For the combined treatment, cells 
were incubated in the presence or absence of calcitriol (50 μM) for 4 h followed 
by stimulation with MIS (71 nM) for 48 h. (A) Western blot analysis of 
caspase-9 and caspase-3; (B) Western blot analysis of Bcl-2 and BAX. Band 
intensities were quantitated and data are presented as mean ± SD. *P < 0.05 vs. 
control; †P < 0.05 vs. MIS. MIS, Müllerian inhibiting substance; Bcl-2, B-cell 
lymphoma-2; BAX, Bcl-2 associated X-protein.
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6. The effects of MIS plus calcitriol on the phosphorylation of ERK in 
SKOV3
Potential molecular mechanisms underlying the synergistic effect of calcitriol 
and MIS were assessed by Western blot analysis following treatment with 
chemical inhibitors: p38 mitogen-activated protein kinase (p38 MAPK) activation 
was inhibited with 20 μM of SB203580 (Sigma); phosphoinositide 3-kinase 
(PI3K) was inhibited with 20 μM LY294002 (Sigma); extracellular 
signal-regulated kinase (ERK) was inhibited with 20 μM of PD98059 (Sigma); 
and c-Jun amino-terminal kinase (JNK) signaling was inhibited with 20 μM of 
SP600125 (Sigma). MIS does not activate the p38 MAPK, PI3K, and JNK 
pathways (data not shown). Figure 5A demonstrates that the ERK pathway is 
activated by MIS. SKOV3 cells were then treated with 71 nM MIS, 20 μM 
PD98059, or both for 2 h and then the degree of apoptosis was analyzed using 
ELISA measuring the level of cellular DNA fragmentation. A significant increase 
in fragmentation was observed for the MIS treatment compared with the control (P
< 0.05) and MIS with PD98059 (P < 0.05) (Fig. 5B). Next, cells were incubated 
with or without calcitriol (50 μM) for 4 h prior to the addition of MIS (71 nM). 
Following 48 h of incubation, cells were harvested and ERK activation was 
analyzed by Western blotting using an anti-phospho-ERK antibody. The 
combination treatment resulted in the most intense specific band compared to 
Control, MIS alone, and calcitriol alone (Fig. 6).
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Fig. 5. The ERK pathway is activated by MIS in SKOV3 cells. (A) Western 
blot analysis of ERK and phosphorylated ERK levels in SKOV3 cells treated 
with MIS. Bands were detected with anti-ERK and anti phospho-ERK antibodies. 
(B) SKOV3 cells were treated with 71 nM MIS, 20 μM PD98059, or both for 2 h 
and the degree of apoptosis was analyzed by ELISA measuring the level of 
18
cellular DNA fragmentation. Significant increase relative to controls (MIS 0 nM) 
is indicated by asterisks and crosses indicate a significant difference (P < 0.05) 
compared with MIS treatment (MIS 71 nM). *P < 0.05 vs. control; †P < 0.05 vs. 
MIS. MIS, Müllerian inhibiting substance; ERK, extracellular signal-regulated 
kinase; ELISA, enzyme-linked immunosorbent assay; OD, optical density.
19
Fig. 6. Calcitriol increased MIS-induced ERK phosphorylation in SKOV3 cells. 
SKOV3 cells were incubated with or without calcitriol (50 μM) for 4 h prior to the 
addition of MIS (71 nM). Subsequent to 48 hours incubation, cells were harvested 
and ERK activation was analyzed by Western blot analysis using 
anti-phospho-ERK antibody. MIS, Müllerian inhibiting substance; Cal, calcitriol; 
ERK, extracellular signal-regulated kinase.
20
IV. DISCUSSION
Our study is aimed at further elucidating the molecular mechanisms underlying 
the anti-proliferative and cancer preventive effects of MIS and calcitriol in order 
to develop strategies to improve OCa treatment. The results of our signal 
transduction studies and in vitro cell culture experiments suggest that calcitriol 
enhances the antitumor activity of MIS in OCa cells by down-regulating the 
expression of Bcl-2 and up-regulating the expression of BAX, caspase-3, and 
caspase-9 through the ERK signaling pathways. 
The clinical use of cytotoxic drugs has had a significant impact on neoplastic 
diseases. However, their therapeutic effectiveness is limited because of their 
narrow therapeutic index and the onset of chemoresistance. Therefore, many 
efforts are currently being directed at finding new therapeutic options that may 
overcome these problems. 
Initial in vitro studies using human OCa cell lines or tissues and several 
follow-up studies have revealed that MIS inhibits the growth of human cancer 
cells including breast, cervical, endometrial, prostate cancer, and ocular 
melanoma.6,8,9,15,16,17 In addition, a recent study indicates that MIS also plays a 
role in cell cycle arrest and apoptosis of endometriosis.18
The prophylactic and therapeutic activities of Vit D against the most common 
types of cancer have been extensively investigated both in vitro and in vivo.19-21
The most striking results have been obtained from studies on breast cancer, 
prostate cancer, and colorectal cancer.19,22 Experimental observations suggest 
that the chemopreventive effects of Vit D are due mainly to its ability to 
modulate important biological functions such as cell proliferation, cell 
differentiation, growth factor gene expression, signal transduction, and 
apoptosis.23,24 Interestingly, recent studies have shown that calcitriol may also 
affect OCa cell proliferation by decreasing human telomerase reverse 
21
transcriptase mRNA through a small non-coding RNA.25
Vit D and TGF-β have similar effects on cell growth and differentiation. 
Experimental stress studies indicate that Vit D may increase the expression 
levels of TGF-β and its receptors or TGF-β secretion in certain cell types.26-28
The Feldman research group has demonstrated that MIS, a TGF-β family 
member, constitutes a novel target gene regulated by calcitriol in prostate cells.14
Exposing prostate cancer cells to calcitriol for 24 h resulted in a considerable 
increase in the expression of MIS mRNA. In addition, HeLa cells transfected 
with an MIS promoter-luciferase construct and a Vit D receptor expression 
vector demonstrated a significant (two- to four-fold) induction of MIS 
promoter-luciferase following treatment with calcitriol, signifying that the MIS 
promoter is responsive to calcitriol.13,14
Determining the utility of MIS as an anticancer drug would most likely involve 
administering MIS to patients as an adjuvant in combination with other drugs. 
Therefore, elucidating the anti-proliferation and apoptosis signaling mechanisms 
downstream of MIS is necessary prior to combining MIS with commonly used 
cytotoxic drugs. Moreover, it is important to test for synergy or additivity 
between MIS and other drugs to ensure that they do not counteract each other. 
Since little is known regarding the signaling pathways by which MIS mediates 
proliferation inhibition and apoptosis in OCa cell lines, we investigated several 
potential molecular mechanisms using chemical inhibitors of the ERK, p38 
MAPK, PI3K, and JNK signaling pathways. Our results demonstrate that MIS is 
not dependent on the p38 MAPK, PI3K, or JNK pathways, but that the ERK 
pathway is activated by MIS. Consistent with our findings, Teixeira et al. 
reported that MIS does not activate the JNK pathway. In addition, they identified 
the JNK inhibitor, SP600125, as an activator of the MIS signal transduction 
pathway.29
Numerous case studies have demonstrated that serum MIS levels can be 
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increased >1000-fold above the normal range without any significant adverse 
reactions; therefore, the therapeutic administration of MIS to cancer patients may 
be well tolerated.10 However, purified recombinant MIS is difficult and 
expensive to obtain, and the clinical use of calcitriol is limited, because of the 
adverse effects of hypercalcemia. Thus, several important issues remain to be 
resolved prior to clinical use, including indication, appropriate doses, blood 
concentration, adverse effects, resistance, drug interactions, and effectiveness in 
vivo.
V. CONCLUSION
Our findings indicate that treatment with MIS in combination with calcitriol may 
be an effective clinical strategy for treating ovarian cancer, as combining the two 
agents enhances the anti-proliferative and apoptotic effects of each agent alone. 
These results, coupled with the need for a decrease in the toxic side effects of 
currently employed therapeutic agents, provide a strong rationale for testing the 
therapeutic potential of MIS, alone or in combination with calcitriol, in the 
treatment of OCa. Future studies should address the exact biological functions of 
MIS and of the extent of the MIS-stimulated anti-proliferative and apoptotic 
activities of calcitriol.
23
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ABSTRACT (IN KOREAN)
난소암 세포주에서 뮐러관 억제물질과 칼시트리올
조합 시 나타나는 증식억제 및 세포사멸 효과
<지도교수 김영태>
연세대학교 대학원 의학과
정 연 수
목적: 임신 7주경 태아 고환의 미숙 세르톨리 세포에서
생산되어 뮐러관을 퇴행시키는 뮐러관 억제물질은 성 발달과
가임기 여성의 생식 내분비 기전을 조절하는 것 외에, 뮐러
관으로부터 발생하는 종양과 세포주의 성장을 생체 내외에서
억제한다는 사실이 밝혀졌다.
비타민 D의 활성 형태인 칼시트리올은 기존의 장, 뼈, 신장, 
부갑상샘에서의 골 관련 대사와 칼슘 항상성을 조절하는 것
외에, 인슐린분비, 면역반응, 분화억제, 증식억제, 세포사멸과
혈관 신생억제, 전이억제 및 항염증작용과 관련하여 주목받고
있다. 또한, 최근 전립선 세포에서 뮐러관 억제물질이
칼시트리올의 주요 표적물질로서, 항암작용 활성에 중요한
역할을 한다고 보고되었다. 이에 난소암 세포주에서 뮐러관
억제물질과 칼시트리올 조합 시 세포의 증식 및 사멸에 미치는
영향과 그 작용기전을 밝히고자 하였다. 
연구 방법: 난소암 세포주인 SKOV3, OVCAR3, OVCA433에서
Western blot 분석을 이용하여, 제2형 뮐러관 억제물질 수용체의
발현 여부를 확인하였다. 각 세포주에서 뮐러관 억제물질과
칼시트리올의 처리농도, 시간에 따른 생존도 변화를 CCK-8
측정법을 통하여 분석하였다. 세포사멸은 DNA 염색 후 흐름
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세포측정기(flow cytometer)로 평가하였고, 뮐러관 억제물질과
칼시트리올에 의해 세포사멸이 유발되는 과정을 Bcl-2, BAX, 
caspase-3, caspase-9의 활성도 측정을 통해 규명하고자 하였다. 
extracellular signal-regulated kinase (ERK), c-Jun amino-terminal kinase, 
p38 mitogen-activated protein kinase, phosphoinositide 3-kinase 
신호전달 체계의 발현은 억제제를 사용한 Western blot 분석을
이용하였다. 
결과: 모든 난소암 세포주에서 제2형 뮐러관 억제물질
수용체의 발현이 관찰되었지만, 발현 정도는 OVCAR3에서 가장
강했다. 모든 세포주는 뮐러관 억제물질과 칼시트리올 각각의
처리농도와 시간에 따라 성장억제 감수성이 증가하였으며, 이는
혼합치료 시 유의하게 증가하였다.
SKOV3에서 뮐러관 억제물질과 칼시트리올에 의한 증식억제
및 세포사멸은 Bcl-2, BAX, caspase-3, caspase-9 단백과 연관이
있었다. 또한, 뮐러관 억제물질은 SKOV3에서 제2형 뮐러관
억제물질 수용체와 결합한 후 ERK 의존적인 신호전달경로를
통해 세포사멸을 유도하였고, 이는 칼시트리올 혼합치료 시
유의하게 증가하였다. 
결론: 난소암 세포주를 이용한 본 연구를 통해, 제2형 뮐러관
억제물질 수용체를 발현하는 난소암에 대하여 생체 외에서
뮐러관 억제물질과 칼시트리올이 효과적인 항종양능을
나타낸다는 사실을 확인하였고, 이에 ERK 신호전달 체계가
관여하는 것으로 사료된다. 향후 보다 큰 규모의 연구를 통해
세포주에 이은 생체 내 연구와 각 신호전달체계의 다른
요소들에 대한 분석이 이루어진다면 제2형 뮐러관 억제물질
수용체를 발현하는 종양의 생물학적 조절제 혹은 치료제로의
개발에 유용한 정보를 제공할 수 있을 것으로 기대한다.
----------------------------------------------------------------------------------------
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